Index to Volume Eighteen

Index of Issues: January–March 1–64: April–June 67–136: July–September 137–200: October–December 201–248.

INDEX OF AUTHORS

A

Aral SO, 10, 92
Athanassopoulou V, 238
Athey TW, 111

B

Bartholow BN, 170
Batteiger BE, 36
Bauriaud R, 76
Benes S, 18
Berrón S, 5
Bertrand M-A, 76
Billings FT III, 129
Bindayna KM, 153
Blanc C, 76
Bolan G, 170
Bosire M, 188
Braddick M, 188
Bridwell MW, 223
Bromberg K, 102
Brothers TA, 223
Brunham RC, 67
Byers RH, 170

C

Caine VA, 36
Calderón E, 72
Cameron DW, 188
Carey RF, 111
Cheong Y-M, 192
Chu M-L, 201
Chutivongse S, 176
Clark JH, 180
Clemens JD, 223
Conde-Glez CJ, 72
Covino JM, 18
Cowan JE, 223
Cummings MC, 18

D

Dallabetta GA, 211
Daniel RW, 183
Danielsson D, 228
Deguchi K, 80
De la Fuente L, 150
Doll LS, 170
Douglas JM Jr, 26, 28, 170
Dowda H, 217
Draft K, 18
Easmon CSF, 153

E

Ehret JM, 28
Eron LJ, 41
Evans VA, 129
Expert Committee on Pelvic Inflammatory Disease, 46

F

Facinelli B, 166
Forslin L, 228
Forssman L, 205
Fragouli E, 238

G

Gamble WB, 217
Gan CY, 84
Geoghegan C, 107
Giesecke J, 205
Gnarpe H, 137
Gnarpe J, 137
Goldstein AMB, 180
González A, 5
Gupta P, 183

H

Hagman M, 228
Harris JR, 133
Harrison JS, 170
Hasselquist MB, 146
Herman BA, 111
Herman WA, 111
Herrmann BF, 233
Hillier S, 146
Hirose T, 80
Hitchcock PJ, 133
Hollis SL, 217
Holmes KK, 21, 133
Hook EW III, 183, 211
Horn JE, 183
Hui Sng E, 201

I

Ison CA, 153

J

Jenkins RR, 138
Joesoef RM, 10
Johannisson G, 205
Johansson AB, 233
Jones JL, 217
Jones RB, 36
Joyce MP, 201
Joy D, 170
Judson FN, 28, 41

K

Kahn JG, 92
Kamala J, 188
Katz BP, 36
Kimata J, 188
Knapp JS, 201
Knud-Hansen CR, 211
Kojima H, 201
Kopp W, 159
Kotloff KL, 223
Kumamoto Y, 80

L

Landers DV, 119
Larsen SA, 124
Larsson G, 137
Lefevre J-C, 76
Lemp GF, 107
Lepargneur J-P, 76
Llaneza JJ, 5
Longshore ST, 217
Luft J, 119
Lutz B, 41

M

Märdh P-A, 1, 233
Marx R, 92
McCormack WM, 18, 195
McGee J, 107
McGee ZA, 69
McKinney KC, 107
McQuillan GM, 183
Mogabgab WJ, 41
Moi H, 228
Montanari MP, 166
Moss PM, 170

N

Ndinya-Achola JO, 188
Neal DP, 107
Ngeow YF, 84
Ngeow Y-F, 192
Ngugi EN, 188
Niruthisard S, 176
Nishimura M, 80

O

Oberle MW, 124
O'Donnell SA, 223
Ohm-Smith MJ, 119
O'Reilly KR, 10
Oriel JD, 89

P

Pabst KM, 211
Palacio V, 5
Patton DL, 21
Pavia AT, 69
Plummer FA, 188
Pólansky M, 143

Q

Quiller CB, 217
Quinn TC, 183, 223

R

Ramachandran S, 192
Ramstedt K, 205
Rand KH, 41
Rauch KJ, 107
Rawstron SA, 102
Ray PA, 183
Reichart C, 211
Retta SM, 111
Rietmeijer CAM, 28
Rinaldi JE, 111
Robbie MO, 119
Robbins SM, 143
Roddy RE, 176
Rolfs RT, 92, 131
Ronald AR, 188
Rosero-Bixby L, 124
Rowen HE Jr, 129
Rutherford GW, 107

S

Sakai S, 80
Sanchez'-Braverman JM, 124
Sarafian SK, 201
Saxena SB, 138
Schable CA, 143
Schachter J, 119, 197
Shah KV, 183
Simonsen JN, 188
Smith BL, 18
Söltz-Szöts J, 159

Soskoline V, 10
Spence MR, 143
Stamm WE, 196
Stary A, 159
Stenberg K, 1
Sterk CE, 92
Sweet RL, 119

T

Tacket CO, 223
Tennican PO, 41
Thejls H, 137
Tseliou P, 238
Tsukamoto T, 80
Tzanakaki G, 238
Tzelepi E, 238

V

Van Hensbroek MB, 28
Varaldo PE, 166
Vàzquez F, 5
Vàzquez JA, 5
Vázquez JA, 150
Vetter KM, 124

W

Waiyaki PG, 188
Walker CK, 119
Wasserheit JN, 133, 211
Wasserman SS, 223
Weller PD, 170
Wickler MA, 180
Wittlinger PS, 129
Wolner-Hanssen P, 21
Wong HC, 84
Woo JM, 107
Wykoff RF, 217

Y

Yap SF, 84

Z

Zenker P, 44
Zishka PA, 26

INDEX OF SUBJECTS

A

Acute salpingitis. *See* Pelvic inflammatory disease
Ampicillin, susceptibility of pelvic inflammatory disease isolates to (Hasselquist & Hillier), 146
Ampicillin/sulbactam, for gonorrhoea (Ngeow, Ramachandran & Cheong), 192
Antibiotic resistance, chromosomal, of gonococci from Bahrain (Bindayna, Easmon & Ison), 153

B

Bahrain, gonococci from, antibiotic chromosomal resistance to (Bindayna, Easmon & Ison), 153

C

Candida albicans urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Cefotaxime, single 500-mg dose, for gonorrhoea (Judson et al.), 41
Cefotetan plus doxycycline, vs. cefoxitin plus doxycycline, for acute salpingitis (Walker et al.), 119
Cefpodoxime, susceptibility of pelvic inflammatory disease isolates to (Hasselquist & Hillier), 146
Ceftizoxime, vs. ceftriaxone, for urethral gonorrhoea (Goldstein, Clark & Wickler), 180
Ceftriaxone, for gonorrhoea
  vs. ceftizoxime (Goldstein, Clark & Wickler), 180
  immediate hypersensitivity to (Zishka & Douglas), 26
Cervical mucosa, nonoxynol-9 toxicity to (Niruthisard, Roddy & Chutivongse), 176
Cervicitis
  gonococcal/chlamydial, surrogate diagnostic methods for (Knud-Hansen et al.), 211
  meningococcal (Conde-Glez & Calderón), 72
Chlamydia trachomatis infection
  case identification methods for, in Sweden (Herrmann, Johansson & Mårdh), 233
  cervical, in pig-tailed macaques (Wolner-Hanssen, Patton & Holmes), 21
  chlamydial conjunctivitis and (Stenberg & Mårdh), 1
  epidemiologic characteristics of (Ramstedt et al.), 205
  in pregnant women, age-related decrease in (Thejls et al.), 137
  7- vs. 21-day tetracycline for (Katz et al.), 36
  surrogate diagnostic methods for (Knud-Hansen et al.), 211
  unsuspected, in heterosexual males (Rietmeijer et al.), 28
  urethral, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Cocaine, sexually transmitted diseases and (Marx et al.), 92
Condoms
  intact, permeability of to viral-sized microspheres (Retta et al.), 111
  prevention of genital ulcer disease by, in prostitutes (Cameron et al.), 188
Congenital syphilis
  failure of maternal therapy and (Rawstron & Bromberg), 102
  new case definition for reporting of (Zenker), 44
Conjunctivitis, chlamydial, genital chlamydial infection and (Stenberg & Mårdh), 1
Contraceptives. *See* Condoms; Nonoxynol-9
Core, concept of, epidemiology and control of sexually transmitted diseases and (Brunham), 67
Costa Rica, population-based serosurveillance of syphilis in (Larsen et al.), 124
Crack cocaine, sexually transmitted diseases and (Marx et al.), 92

D

Doxycycline, susceptibility of pelvic inflammatory disease isolates to (Hasselquist & Hillier), 146
Drug abuse. *See* Crack cocaine

E

Endocervical gram stain, in diagnosis of gonococcal/chlamydia cervicitis (Knud-Hansen et al.), 211

F

French men, *U. urealyticum* urethritis in (Lefevre et al.), 76

G

Gardnerella vaginalis urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Genital human papillomavirus infection, in inner city STD clinic patients (Horn et al.), 183
Genital ulcer disease, prevention of by condoms, in prostitutes (Cameron et al.), 188
Gonococcal cervicitis, surrogate diagnostic methods for (Knud-Hansen et al.), 211
Gonococcal meningitis, primary (Billings et al.), 129
Gonococci, from Bahrain, chromosomal antibiotic resistance to (Bindayna, Easmon & Ison), 153
Gonorrhoea
  ceftriaxone for, immediate hypersensitivity to (Zishka & Douglas), 26

in female prostitutes (Vàzquez et al.), 5
latent, Emil Noeggerath and (Oriel), 89
ofloxacin for (Smith et al.), 18
single 500-mg dose of cefotaxime for (Judson et al.), 41
sulbactam/ampicillin for (Ngeow, Ramachandran & Cheong), 192
urethral, ceftizoxime vs. ceftriaxone for (Goldstein, Clark & Wickler), 180
Gram stain, endocervical, in diagnosis of gonococcal/chlamydia cervicitis (Knud-Hansen et al.), 211
Greece, *N. gonorrhoeae* in, epidemiologic classification and antibiotic susceptibility of (Tzelepi et al.), 238

H

Haemophilus parainfluenzae urethritis (Facinelli, Montanari & Varaldo), 166
Haemophilus parainfluenzea urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Hepatitis B infection, among Chinese STD patients in Kuala Lumpur, Malaysia (Gan et al.), 84
High-risk behavior, in homosexual men (Doll et al.), 170
Homosexual men, high-risk behavior in (Doll et al.), 170
Human immunodeficiency virus, type I, seroprevalence of antibodies to in family-planning population (Spence et al.), 143
Human immunodeficiency virus infection
partner notification for (Rutherford et al.), 107
in rural South Carolina (Wykoff et al.), 217
voluntary serosurvey and risk assessment for, in college students (Kotloff et al.), 223
Human papillomavirus infection, in inner city STD clinic patients (Horn et al.), 183

K

Kampmeier, Rudolph H., obituary, 195

L

β-Lactamase plasmid, Toronto, in penicillinase-producing isolates of *N. gonorrhoeae* (Sarafian et al.), 201
β-Lactamase production, in *N. gonorrhoeae* (Nishimura et al.), 80
Leukocyte esterase dipstick method, in diagnosis of gonococcal/chlamydia cervicitis (Knud-Hansen et al.), 211

M

Macaques, *C. trachomatis* cervicitis in (Wolner-Hanssen, Patton & Holmes), 21
Meningitis, gonococcal, primary (Billings et al.), 129
Meningococcus, urogenital infection due to (Conde-Glez & Calderón), 72
Metronidazole, susceptibility of pelvic inflammatory disease isolates to (Hasselquist & Hillier), 146
Mucosal toxicity, nonoxynol-9 (Niruthisard, Roddy & Chutivongse), 176

N

Neisseria gonorrhoeae
African-type penicillinase-producing strains of isolated in Spain, enzyme analysis of (de la Fuente & Vazquez), 150
beta-lactamase production in and auxotypes of (Nishimura et al.), 80
epidemiologic classification and antimicrobial susceptibility of, in Athens, Greece (Tzelepi et al.), 238
penicillinase-producing isolates of, Toronto beta-lactamase plasmid in (Sarafian et al.), 201
Neisseria gonorrhoeae urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Neisseria meningitidis
urogenital infection due to (Conde-Glez & Calderón), 72
in urogenital specimens (Hagman et al.), 228
Noeggerath, Emil, and "latent" gonorrhea (Oriel), 89
Nonoxynol-9, frequent use of, local toxicity of (Niruthisard, Roddy & Chutivongse), 176

O

Ofloxacin, for gonorrhea (Smith et al.), 18

P

Parran Award, given to Julius Schachter, 197
Partner notification
for human immunodeficiency virus infection (Rutherford et al.), 107
in rural South Carolina (Wykoff et al.), 217
Partner recruitment, as STD risk factor (Aral et al.), 10
Pelvic inflammatory disease
antibiotic susceptibility of isolates from (Hasselquist & Hillier), 146
cefotetan plus doxycycline vs. cefoxitin plus doxycycline for (Walker et al.), 119
new directions in prevention and management of (Rolfs), 131
1990 research directions for (Expert Committee on PID), 46
Penicillin, maternal treatment with, and prevention of congenital syphilis (Rawstron & Bromberg), 102
Pig-tailed macaques, cervical infection with *C. trachomatis* in (Wolner-Hanssen, Patton & Holmes), 21
Prophylactics
intact, permeability of to viral-sized microspheres (Retta et al.), 111
prevention of genital ulcer disease by, in prostitutes (Cameron et al.), 188
Prostitutes
condoms for prevention of genital ulcer disease in (Cameron et al.), 188
Viennese, health care for (Stary, Kopp & Söltz-Szöts), 159

S

Salpingitis, acute. *See* Pelvic inflammatory disease
Schachter, Julius, receives Parran Award, 197
Sex partner. *See under* Partner
Sexual behavior, high-risk, in homosexual men (Doll et al.), 170
Sexually transmitted diseases. *See also specific diseases*
"agents" of, conceptual validity of (McGee & Pavia), 69
crack cocaine and (Marx et al.), 92
development of diagnostics for resource-limited settings for (Hitchcock et al.), 133
epidemiology and control of, concept of core and (Brunham), 67
sex partner recruitment as risk factor in (Aral et al.), 10
in Viennese prostitutes, health care for (Stary, Kopp & Söltz-Szöts), 159
Spain, African-type penicillinase-producing *N. gonorrhoeae* strains isolated in, enzyme analysis of (de la Fuente & Vázquez), 150
Streptococcus agalactiae urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Substance abuse. *See* Crack cocaine
Sulbactam/ampicillin, for gonorrhoea (Ngeow, Ramachandran & Cheong), 192

Sweden, *C. trachomatis* infection case identification methods in (Herrmann, Johansson & Mårdh), 233
Syphilis
congenital
failure of recommended maternal therapy and (Rawstron & Bromberg), 102
new case definition for reporting of (Zenker), 44
population-based serosurveillance of, in Costa Rica (Larsen et al.), 124

T

Tetracycline, 7- vs. 21-day course of, for *C. trachomatis* (Katz et al.), 36
Toronto beta-lactamase plasmid, in penicillinase-producing isolates of *N. gonorrhoeae* (Sarafian et al.), 201
Trichomonas vaginalis, prevalence of in high-risk men (Saxena & Jenkins), 138
Trichomonas vaginalis urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76

U

Ulcers, genital, prevention by condoms, in prostitutes (Cameron et al.), 188
Ureaplasma urealyticum urethritis, clinical and microbiologic features of, in French men (Lefevre et al.), 76
Urethritis
clinical and microbiologic features of, in French men (Lefevre et al.), 76
gonococcal, ceftizoxime vs. ceftriaxone for (Goldstein, Clark & Wickler), 180
Haemophilus parainfluenzae and
(Facinelli, Montanari & Varaldo), 166
(Lefevre et al.), 76
meningococcal (Conde-Glez & Calderón), 72

V

Vaginal mucosa, nonoxynol-9 toxicity to (Niruthisard, Roddy & Chutivongse), 176
Viennese prostitutes, health care for (Stary, Kopp & Söltz-Szöts), 159

W

Warts, genital, in inner city STD clinic patients (Horn et al.), 183

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685. Title 39 United States Code) Date of Filing—October 1, 1991). Title of Publication—SEXUALLY TRANSMITTED DISEASES; Frequency of Issue—Quarterly; Annual Subscription Price—$100.00; Location of Known Office of Publication—100 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of the Publisher—227 East Washington Square, Philadelphia, PA 19106; Publisher—J. B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Editor—Julius Schachter, M.D., University of California, San Francisco, Building 30, Room 416, San Francisco General Hospital, San Francisco, CA 94110; Managing Editor—Lynda Krumpholz, 227 East Washington Square, Philadelphia, PA 19106; Owner—American Venereal Disease Association, Box 22349, San Diego, CA 92112; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 2,713, actual 2,200 B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,892, actual 1,914; C. Total paid circulation, average 1,892, actual 1,914; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 90, acutal 50; E. Total distribution (*sum of C and D*), average 1,982, actual 1,964; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 731, acutal 236; 2. Returns from news agents, none; G. Total (*sum of E & F—should equal net press runs shown in A*), average 2,713, actual 2,200. I certify that the statements made by me above are correct and complete. Joseph W. Lippincott III, *Publisher*.